Wikipédia

Utilisateur:Lyokoï/Brouillon

< Utilisateur:Lyokoï

Le Trouble Dysphorique Prémenstruel (TDPM) est une forme sévère et handicapante du syndrôme pré-menstruel qui affecte de 1,8 à 5,8% des femmes menstruées[1]. Le trouble se manifeste par le biais de symptômes comportementaux et somatiques qui se reproduisent mensuellement durant la phase lutéale du cycle menstruel[2],[3]. Il affecte les femmes de leur puberté jusqu'à leur ménopause, à l'exception de celles atteintes d'aménorrhée hypothalamique, ou durant la grossesse ou l'allaitement[4]. Les femmes atteintes de TPDM ont un un taux de suicide plus élevé, avec notamment un taux de pensées suicidaires 2,8% fois plus élevées, un historique de planification suicidaire 4,15% et un taux de tentative de suicide 3,3 fois plus élevé[5].

The emotional effects of premenstrual dysphoric disorder are theorized to be the result of severe gonadal steroid fluctuations, as they cause dysregulation of serotonin uptake and transmission, and potentially calcium regulation, circadian rhythm, BDNF, the HPA-axis and immune function as well.[6] Some studies have suggested that those who with PMDD are more at risk of developing postpartum depression after pregnancy, but other evidence has been found to suggest against that notion.[7] PMDD was added to the list of depressive disorders in the Diagnostic and Statistical Manual of Mental Disorders in 2013.[1] It has 11 main symptoms, and a woman has to exhibit at least five to qualify for PMDD.[6] Roughly 20% of menstruating women have some symptoms of PMDD, but either have less than five or do not have functional impairment.[8]

Treatment is often with antidepressants such as selective serotonin reuptake inhibitors (SSRIs) as well as ovulation suppression using birth control pills and GnRH analogues.[3] SSRIs are the most common treatment, as they tend to improve both the physical and emotional symptoms as well as the general behavior and functionality of the woman.[3]

Définitions modifier

Signs and symptoms modifier

Le trouble dysphorique prémenstruel (TDPM) est une forme sévère du syndrôme prémenstruel (SPM). De la même manière que le SPM, le trouble dysphorique prémenstruel suit un pattern cyclique prédictible. Les symptômes commencent dans la fin de la phase lutéale du cycle menstruel (après l'ovulation) et finissent peu après le début des menstruations[9]. En moyenne les symptômes durent six jours mais peuvent commencer jusqu'à deux semaines avant les règles, ce qui signifie que les symptômes peuvent être ressenti jusqu'à trois semaines durant un cycle. Les symptômes sévères s'aggravant jusqu'au début des menstruations, dont beaucoup ne ressentiront le soulagement seulement quelques jours après la fin des menstruations. Les symptômes les plus intenses ont lieu durant la semaine et les jours précédents le premier jour de saignement[2]. Les symptômes s’arrêtent généralement rapidement après le début des menstruations ou quelques jours après qu'elles se soient terminées[3][10]. L'apparition de symptômes uniquement pendant ou autour de la phase lutéale est primordial pour diagnostiquer une femme souffrant de TDPM plutôt que n'importe quel autre trouble de l'humeur[4]. Les symptômes peuvent être physiques également, mais des symptômes reliés à l'humeur doivent être présents pour le diagnostic[9]. Les femmes souffrant du TDPM peuvent avoir des pensées suicidaires[11]. Un journal d'humeur permettant d'enregistrer les changements et rythmes émotionnels peut aider à la gestion du trouble[4].

La société internationale pour l'étude des troubles prémenstruels (ISPMD - International Society for the Study of Premenstrual Disorders) définit deux catégories de troubles prémenstruels : trouble prémenstruel central (core pmd) et trouble prémenstruel associé (variant PMD)[4] :

  • Le trouble prémenstruel central a six caractéristiques, toutes principalement axées sur la nature cyclique du TDPM et l'apparition typiques des symptômes pendant la phase prémenstruelle constatées au cours de plus de deux cycles menstruels[4].
  • Les quatre troubles prémenstruels associés classés impliquent des variables différentes liés à l'apparition d'une détresse prémenstruelle ; tels que, le trouble prémenstruel sans menstruation, ou bien l'exacerbation prémenstruelle, où les symptômes d'un trouble psychologique, somatique ou médical sous-jacent s'aggravent considérablement de façon prémenstruelle[4].

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS). Like PMS, premenstrual dysphoric disorder follows a predictable, cyclic pattern. Symptoms begin in the late luteal phase of the menstrual cycle (after ovulation) and end shortly after menstruation begins.[9] On average, the symptoms last six days but can start up to two weeks before menses, meaning symptoms can be felt for up to three weeks out of a cycle. Severe symptoms can begin and worsen until the onset of menstruation, with many not feeling relief until a few days after menstraution ends. The most intense symptoms occurring in the week and days leading up to the first day of menstrual blood flow.[2] The symptoms usually cease shortly after the start of the menstrual period or a few days after it ending.[3][12] The onset of symptoms only during or around the luteal phase is key for diagnosing a woman with PMDD rather than any other mood disorders.[4]

The symptoms can be physical or emotional, but mood symptoms must be present for the diagnosis.[9] Women with PMDD may have thoughts of suicide.[11] A mood log in which a woman records mood patterns over time may help direct.[4]

The International Society for the Study of Premenstrual Disorders (ISPMD) defines two categories of premenstrual disorders: core PMD and variant PMD.[4]

Core PMD has six characteristics, all mainly focusing on the cyclical nature of PMDD and its typical onset pre-menses tracked over the course of more than two menstrual cycles. The four classified Variant PMDs involve more unexpected variables that cause the onset of premenstrual distress; such as, PMD with absent menstruation or premenstrual exacerbation, wherein the symptoms of another preexisting psychological disorder may be heightened as a result of PMDD onset.[4]

Autres maladies connexes : modifier

* Des troubles bipolaires, de l'anxiété, et autres troubles dépressifs et mentaux majeurs sont fortement liés au TDPM[13]. Les personnes atteintes de TDPM ont 50 à 78% de probabilités d'être atteintes au cours de leur vie par des troubles psychiatriques de plusieurs type, comme de l'anxiété généralisée (ou TAG, trouble anxieux généralisé), de la dépression saisonnière (ou TAS, trouble affectif saisonnier), et des troubles dépressifs majeurs[3].

Bipolar depression, anxiety disorders, and other Axis I disorders are more common in those with PMDD.[13] In women with PMDD, there is a 50-78% lifetime incidence of various psychiatric disorders such as generalized anxiety disorder, seasonal affective disorder, and major depressive disorder.[3]

Cause modifier

Les troubles de l'humeur dûs au TDPM sont présents uniquement chez les femmes menstruées. Pendant les grossesses et après la ménopause, ces symptômes n'apparaissent pas chez ces mêmes femmes. D'autres troubles de l'humeur, cependant, peuvent persister tout au long de la période de reproduction, et sont totalement indépendants du cycle (ou de l'absence de cycle) de ces femmes[14].

PMDD mood symptoms are only present in menstruating women. Thus, symptoms do not occur during pregnancy and after menopause. Other mood disorders typically persist across all reproductive life events and are independent of a woman's menstrual cycle or lack thereof.[15]


The most agreed-upon possibilities for what causes PMDD currently are heightened sensitivity to fluctuating levels of certain hormones (i.e. the reproductive hormones), environmental stress, and genetic predisposition.[4] The sex steroids—estrogen and progesterone—are neuroactive; they have been noted in rat models to be involved in serotonin pathways.[4] Serotonin is involved in mood regulation alongside estrogen, whose receptors are found in the prefrontal cortex and hippocampus—the regions most known for their involvement in regulating one's mood and cognition overall.[2][4]

*Il y a plusieurs explications plausibles sur ce qui peut causer le TPDM. Les hypothèses les plus communément admises sont une haute sensibilité à la fluctuation du taux de certaines hormones (en particulier les hormones liées à la reproduction), un environnement (travail, famille, situation personnelle) causant du stress, et des prédispositions génétiques. [4] Les stéroïdes sexuels (l'oestrogène et la progésterone) sont des neuroactifs. On a noté, en faisant des expériences sur des rats de laboratoire, que ces hormones sont impliquées dans l'acheminement de la sérotonine. [4] La sérotonine est elle-même impliquée dans des circuits de régulation de l'humeur (de même que l'oestrogène). Les récepteurs de la sérotonine se trouvent dans le cortex pré-frontal et dans l'hippocampe, des régions du cerveau bien connues pour la régulation de l'humeur et les activités cognitives en général.[2][4]


While the timing of symptoms suggests hormonal fluctuations as the cause of PMDD, a demonstrable hormonal imbalance in women with PMDD has not been identified. In fact, levels of reproductive hormones and their metabolites in women with and without PMDD are indistinguishable.[16][17][18] It is instead hypothesized that women with PMDD are more sensitive to normal levels of hormone fluctuations, predominantly estrogen and progesterone, which produces biochemical events in the nervous system that cause the premenstrual symptoms.[18] These symptoms are more predominant in women who have a predisposition to the disorder.[9]

*Bien que l'apparition spécifique des symptômes du TPDM à certains moments du cycle suggère des fluctuations hormonales chez les personnes atteintes, on a pas encore pu identifier un désordre hormonal notable chez les femmes atteintes. En fait, on ne distingue aucune différence concernant les niveaux d'hormones liées à la reproduction, ainsi que leurs métabolites associés, chez une femme atteinte de TDPM et chez une femme non atteinte.[16][17][18] L'hypothèse la plus probable à ce jour étant que les femmes atteintes de TPDM sont en fait plus sensibles à des changements tout à fait classiques de fluctuations d'hormones, principalement l'oestrogène et la progestérone, qui produisent biochimiquement les syndromes prémenstruels dans le système nerveux. [18] Ces symptômes seront prédominants chez les femmes ayant une prédisposition au TPDM. [9]


It is apparent that the premenstrual disorders are biologically driven and are not only psychological or cultural phenomena. PMDD has been reported by menstruating women worldwide, indicating a biological basis that is not geographically selective.[2] Most psychologists infer that this disorder is caused by both a reaction to hormone flux and also genetic components. There is evidence of heritability of (retrospectively-reported) premenstrual symptoms from several twin and family studies done in the 1990s, with the heritability of PMDD proving to be about 56%.[19][20][21]

*C'est donc assez évident de constater que les troubles prémenstruels sont induits biologiquement, et non seulement de façon psychologique, ou par effet de mode. Le TDPM a été constaté chez des femmes de n'importe quelle origine, partout sur Terre, ce qui induit vraiment une cause biologique, et pas une cause géographique et/ou ethnique.[2] La plupart des psychologues et psychiatres notent que ce trouble peut être causé à la fois par une réaction aux fluctuations hormonales, et aussi à des composantes génétiques. Il y a des preuves d'une prédisposition génétique (constatée rétrospectivement) grâce à des études sur les symptômes prémenstruels parmi des jumelles, et des études sur des familles faites durant les années 90. Ces études montrent que dans 56% des cas, l'hérédité et la génétique jouent dans la transmission de ce trouble.


Disorders of this nature are often caused by a mix of both environmental and biological factors. Environmental stressors have also been found to prospectively increase risk for PMDD symptoms.[22][23] Genetics do not operate in a vacuum: environmental components such as stress, hormonal fluctuation, and epigenetics play a key role in the pathology and onset of the disorder.[24] Some studies have noted evidence of interpersonal trauma (domestic violence, physical or emotional trauma, or substance abuse) or seasonal changes (making PMDD potentially comorbid with Seasonal Affective Disorder) having an impact on PMDD risk.[3][25] But the most common pre-existing disorder found in those diagnosed with PMDD is major depression, wherein they either actually had it or were misdiagnosed when they should have only been diagnosed with PMDD.[25] The last environmental factor is primarily sociological: the sociocultural aspects of being female, performing female gender roles, and stress from engaging in female sexual activity.[1]

*Des troubles de cette nature sont souvent dûs à un mix de facteurs environnementaux et d'ordre biologiques. Le stress environnemental augmente fortement le risque de développer des symptômes de TPDM.[22][23] L'hérédité intervient elle aussi, mais dans un certain contexte: le stress, les fluctuations d'hormones et l'épigénétique jouent un rôle clé dans cette pathologie et le déclenchement de cette maladie.[24] Certaines études ont constaté que des traumatismes (comme de la violence domestique, des traumas physiques ou émotionnels, ou encore l'abus de drogues et autres substances), ainsi que les changements de saisons (le TAS cité plus haut marche vraiment de concert avec le TPDM, et augmente sa dangerosité) ont un impact sur les risques liés au TPDM.[3][25] Mais c'est la dépression majeure que l'on retrouve le plus dans le suivi médical des femmes atteintes de TPDM. Elles peuvent avoir été réellement diagnostiquées pour dépression majeure, ou simplement avoir eu une erreur de diagnostic, elles étaient peut être juste atteintes de TPDM, et non pas de dépression majeure. [25] Le dernier facteur environnemental qui joue énormément est tout bonnement d'ordre sociologique: le fait d'être une femme dans notre société, d'accepter de se conformer au rôle que l'on assigne au genre féminin et d'en adopter les codes, et aussi le stress pouvant être lié à une activité sexuelle.[1]

AurCal: J'ai l'impression que ces deux paragraphes se répètent un peu, là j'ai fait de la traduction littérale, mais ya peut être moyen de regrouper tout ça.


Relationship to pregnancy modifier

*TPDM et grossesse

Women with PMDD usually see their symptoms disappear while they are pregnant. Premenstrual dysphoric disorder is primarily a mood disorder that is associated with onset of menstruation; pregnancy, menopause, and hysterectomies all cause menstruation to cease, thereby stopping the proposed sex steroid-/serotonin-caused symptoms from occurring.[26][27] Although one might expect a higher rate of postpartum depression among those with PMDD, a large study of women with prospectively-confirmed PMDD did not find a higher prevalence of postpartum depression than in controls.[7][27] If a woman had experienced PPD beforehand, there was found to be a less-than 12% chance of PMDD pathology emerging—hardly any differentiation from the regular population of those who have never experienced postpartum depression.[27] However, PMDD symptoms can get worse following pregnancy, or other associated events such as birth and miscarriage.[11]

Menopause launches a woman into an associated mood disorder called climacteric depression.[7] The permanent stopping of the menstrual cycle causes a myriad of physiological and psychological symptoms and issues, all associated with the natural estrogen deficiency post-menopause.[7]

*Les personnes atteintes de TPDM voient généralement leurs symptômes disparaître lorsqu'elles sont enceintes. Ces troubles de l'humeurs sont associés au cycle menstruel, comme le nom l'indique. Ils cessent quand cessent les menstruations: en période d'aménorrhée, durant une grossesse, la ménopause, ou en cas d'hystérectomie: quand les stéroïdes sexuels qui causent ces symptômes sont stoppés, les symptômes cessent. On pourrait s'attendre à ce que les personnes atteintes de TPDM soient susceptibles d'être plus atteintes de dépression postpartum, mais en fait suivant certaines études il n'y a pas de différences entre l'échantillon composé de personnes atteintes et l'échantillon de contrôles. Par contre, si une femme a été atteinte de dépression post partum , on a pu observer qu'il y avait moins de 12% de probabilités qu'une pathologie comme le TPDM advienne après la grossesse. Ce taux de probabilités est somme toute le même que sur un échantillon qui n'a connu la dépression post partum. Par contre, le TPDM et ses effets dévastateurs peuvent être accentués après les expériences suivantes: grossesse, naissance, ou fausse couches.

Diagnosis modifier

Diagnostic criteria for PMDD are provided by a number of expert medical guides. Diagnosis can be supported by having women who are seeking treatment for PMDD use a daily charting method to record their symptoms.[4] Daily charting helps to distinguish when mood disturbances are experienced and allows PMDD to be more easily distinguished from other mood disorders. With PMDD, mood symptoms are present only during the luteal phase, or last two weeks, of the menstrual cycle.[9] While PMDD mood symptoms are of a cyclical nature, other mood disorders are variable or constant over time. Although there is a lack of consensus on the most efficient instrument by which to confirm a PMDD diagnosis, several validated scales for recording premenstrual symptoms include the Calendar of Premenstrual Experiences (COPE), Daily Record of Severity of Problems (DRSP), and Prospective Record of the Severity of Menstruation (PRISM).[28][29] In the context of research, standardized numerical cutoffs are often applied to verify the diagnosis.[28] The difficulty of diagnosing PMDD is one reason that it can be challenging for lawyers to cite the disorder as a defence of crime, in the very rare cases where PMDD is allegedly associated with criminal violence.[30]

DSM-5 modifier

The DSM-5 which established seven criteria (A through G) for the diagnosis of PMDD.[1] There is overlap between the criteria for PMDD in the DSM-5 and the criteria found in the Daily Record of Severity of Problems (DRSP).[28][29]

According to the DSM-5, a diagnosis of PMDD requires the presence of at least five of these symptoms with one of the symptoms being numbers 1-4.[1] These symptoms should occur during the week before menses and remit after initiation of menses. In order to meet criteria for the diagnosis, the symptoms should be charted prospectively for two consecutive ovulation cycles in order to confirm a temporal and cyclical nature of the symptoms. The symptoms should also be severe enough to affect normal work, school, social activities, and/or relationships with others.[1]

The symptoms of Criteria A-C must have been met for most menstrual cycles that occurred in the preceding year, and have to have affected normal functioning to some degree (Criterion D).

Criterion A: During most menstrual cycles throughout the past year, at least 5 of the following 11 symptoms (especially including at least 1 of the first 4 listed) must be present in the final week before the onset of menses, must start to improve within a few days after the onset of menses, and become minimal or absent in the week post-menses:[1]

  1. Marked lability (e.g., mood swings)
  2. Marked irritability or anger
  3. Markedly depressed mood
  4. Marked anxiety and tension
  5. Decreased interest in usual activities
  6. Difficulty in concentration
  7. Lethargy and marked lack of energy
  8. Marked change in appetite (e.g., overeating or specific food cravings)
  9. Hypersomnia or insomnia
  10. Feeling overwhelmed or out of control
  11. Physical symptoms (e.g., breast tenderness or swelling, joint or muscle pain, a sensation of bloating and weight gain)[1][3]

Criterion B: One (or more) of the following symptoms must be present:[1]

  1. Marked affective lability (e.g., mood swings, feeling suddenly sad or tearful, or increased sensitivity to rejection)
  2. Marked irritability or anger or increased interpersonal conflicts
  3. Marked depressed mood, feelings of hopelessness, or self-deprecating thoughts
  4. Marked anxiety, tension, and/or feelings of being keyed up or on edge

Criterion C: One (or more) of the following symptoms must be present additionally, to reach a total of 5 symptoms when combined with present symptoms from Criterion B above:[1]

  1. Decreased interest in usual activities (e.g., work, school, friends, hobbies).
  2. Subjective difficulty in concentration.
  3. Lethargy, easy fatigability, or marked lack of energy.
  4. Marked change in appetite; overeating; or specific food cravings.
  5. Hypersomnia or insomnia.
  6. A sense of being overwhelmed or out of control.
  7. Physical symptoms such as breast tenderness or swelling, joint or muscle pain, a sensation of "bloating," or weight gain.

Criterion D: The symptoms observed in Criteria A-C are associated with clinically significant distress or interference with work, school, usual social activities, or relationships with others (e.g., avoidance of social activities; decreased productivity and efficiency at work, school, or home).[1]

  • Clinically significant distress is not defined explicitly by the DSM-IV, where it has been critiqued by multiple scholars as being too vague, and potentially detrimental for those who have symptoms of depression, anxiety, or other mood disorders because they do not meet the clinical significance requirement.[31][32]

Criterion E: The disturbance is not merely an exacerbation of the symptoms of another disorder, such as major depressive disorder, panic disorder, persistent depressive disorder (Dysthymia), or a personality disorder—although it may co-occur with any of these disorders.[1]

Criterion F: Criterion A should be confirmed by prospective daily ratings during at least two symptomatic cycles. The diagnosis may be made provisionally prior to this confirmation.[1]

Criterion G The symptoms are not attributable to the physiological effects of a substance (e.g., drug abuse, a medication, other treatments) or another medical condition (e.g., hyperthyroidism).[1]

ICD 11 modifier

Diagnostic criteria for PMDD are also provided by the 2016 World Health Organization's International Classification of Diseases (ICD-11-CM):[33][34]

GA34.41 Premenstrual dysphoric disorder

Description

During a majority of menstrual cycles within the past year, a pattern of mood symptoms (depressed mood, irritability), somatic symptoms (lethargy, joint pain, overeating), or cognitive symptoms (concentration difficulties, forgetfulness) that begin several days before the onset of menses, start to improve within a few days after the onset of menses, and then become minimal or absent within approximately 1 week following the onset of menses. The temporal relationship of the symptoms and luteal and menstrual phases of the cycle may be confirmed by a prospective symptom diary. The symptoms are severe enough to cause significant distress or significant impairment in personal, family, social, educational, occupational or other important areas of functioning and do not represent the exacerbation of a mental disorder.

Early drafts of the ICD did not recognize PMDD as a separate condition.[35] In the World Health Organisation's classification system, the International Classification of Diseases (ICD-11), PMDD is listed as a "disease of the genitourinary system".[36]

Other modifier

Other organizations that have published diagnostic criteria for PMDD include the Royal College of Obstetricians and Gynecologists and the International Society for the Study of Premenstrual Disorders (ISPMD).[37][33] The ISPMD was a consensus group established by an international multidisciplinary group of experts. The group's diagnostic criteria for PMDD focuses on the cyclic nature of the symptoms occurring during the luteal phase of the menstrual cycle, as well as the symptoms being absent after menstruation and before ovulation and causing significant impairment. The ISPMD diagnostic criteria for PMDD do not specify symptom characteristics or number of symptoms.[37]

In 2003 the Committee for Proprietary Medicinal Products required the manufacturer of fluoxetine to remove PMDD from the list of indications in Europe.[38] In Australia, PMDD is recognized by the Therapeutic Goods Administration. However, antidepressants are not reimbursed for PMDD under the Pharmaceutical Benefits Scheme.[39]

Differential diagnosis modifier

In addition to Axis I disorders, several other medical illnesses such as chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, and migraine disorder may present symptoms similar or identical to those of PMDD.

The symptoms which coincide with mood disorders, i.e. major depressive disorder or bipolar disorder, may worsen during the premenstrual period and thus may mimic PMDD. This phenomenon is known as premenstrual exacerbation (PME) and refers to the worsening of mood disorder symptoms during the premenstrual phase. An estimated 40% of those who seek treatment for PMDD are found to not have PMDD, but rather a PME of an underlying mood disorder.[40]

Treatment modifier

Medication modifier

Several medications have received empirical support for the treatment of PMDD. Selective serotonin reuptake inhibitors (SSRIs) are the first-line medication.[9][41][42] The U.S. Food and Drug Administration (FDA) has approved four SSRIs for the treatment of PMDD: Fluoxetine (available as generic or as Prozac or Sarafem), sertraline (Zoloft), paroxetine (Paxil), and escitalopram oxalate (Lexapro).[43] Unlike treatments for depressive disorders, SSRIs do not need to be taken daily but instead can be taken only in the luteal phase or during PMDD symptoms.[3] This is because those who respond to SSRIs usually experience symptoms relief within 1–2 days.[44] Studies in rats suggest this rapid response to SSRIs is due to the elevation of the neuroactive progesterone metabolite allopregnanolone in the brain, rather than serotonin.[45][46] Luteal phase dosing can be started 14 days before menses and subsequently discontinued after start of menstrual flow.[43] Women taking SSRIs to ease PMDD generally report >50% alleviation in symptoms, which was significant improvement compared to placebo.[44]

Although less studied, SNRIs have also shown benefits for those with PMDD. In a randomized, controlled clinical trial of women with PMDD, 60% of the subjects taking venlafaxine (Effexor) improved, versus 35% on placebo. Improvement was noticed during the first treatment cycle with 80% symptom reduction.[47]

Another FDA approved treatment for PMDD is the oral contraceptive with ethinylestradiol and drospirenone (a novel progestin) taken on a 24-4 schedule (24 active pills, 4 inactive pills).[43] It has been shown that hormonal birth control containing drospirenone and low levels of estrogen helps relieve severe PMDD symptoms, for at least the first three months that it is used.[48] The idea behind using oral contraceptives is to suppress ovulation, therefore suppressing sex hormone fluctuations.

Another treatment, typically used when other options have failed, is injection of a gonadotropin-releasing hormone agonist.[49] These drugs create a temporary, drug-induced menopause-like condition. Addback of estradiol is recommended to prevent bone loss long-term; this generally necessitates the concurrent addback of progesterone to prevent estradiol-induced endometrial hyperplasia. Two landmark studies have demonstrated that the addback of estradiol or progesterone on top of GnRH agonists can cause a resurgence of PMDD symptoms but that this resurgence of symptoms remits after one month of stable addback.[50][51][52]

Psychotherapy modifier

Cognitive behavioral therapy (CBT) has been shown to be effective for reducing premenstrual symptoms in women with (retrospectively-reported) PMS.[53] CBT is an evidence-based approach for treating depression and focuses on the link between mood, thoughts, and actions to help people address current issues and symptoms. When CBT was compared to SSRI alone or in combination with SSRI, groups receiving CBT had significant improvement of PMS symptoms.[53] Through the practice of CBT, people are better able to recognize and modify recurrent issues as well as thought and behavior patterns that interfere with functioning well or that make depressive symptoms worse. However, a recent meta-analysis suggests that existing psychotherapies may be primary useful for reducing impairment (rather than symptom severity) in PMDD.[53]

Surgery modifier

When drug-based treatments are ineffective or produce significant side effects, then removing the ovaries through oophorectomy can produce an immediate and permanent cure.[26] Typically, the uterus is removed during the same surgery, and the woman is prescribed a low-dose estrogen patch to reduce the symptoms produced by surgically induced menopause.[26]

Epidemiology modifier

A majority of menstruating women have feeling of premenstrual symptoms to some degree, with 20-30% feeling enough symptoms to qualify for diagnosis of PMS and 3-8% of that group qualifying for the diagnosis of PMDD.[2][3] With only a small fraction feeling such intense distress linked to the onset of menstruation, any fear of social pathologizing of normal emotional and physical symptoms as a result of menstruation is unnecessary; PMDD is distinct, and having it included in the DSM-5 works to affirm that.[25]

History modifier

The diagnostic category was discussed in the DSM-IIIR (1987), in which the proposed condition was named "Late Luteal Phase Dysphoric Disorder" and was included in the appendix as a proposed diagnostic category needing further study.[54] Preparations for the DSM-IV led to debate about whether to keep the category at all, only keep it in the appendix, or remove it entirely; the reviewers determined that the condition was still too poorly studied and defined, so it was kept in the appendix but elaborated with diagnostic criteria to aid further study.[27][55]

As preparations were underway in 1998 for the DSM-IV-TR, the conversation changed, as Eli Lilly and Company paid for a large clinical trial of fluoxetine as a potential treatment for the condition that was then conducted by Canadian academics and published in the New England Journal of Medicine in 1995.[56] Other studies have been conducted as well, wherein all found that approximately 60% of women with PMDD in the trials improved with the drug; representatives from Lilly & Co. and the FDA participated in the discussion.[27][55]

Various strong stances were taken in said discussion. Sally Severino, a psychiatrist, argued that because symptoms were more prevalent in the United States, PMDD was a culture-bound syndrome and not a biological condition; she also claimed it unnecessarily pathologized the hormonal changes of the menstrual cycle.[27] Jean Endicott, another psychiatrist and chair of the committee, has argued that it was a valid condition from which women suffer and should be diagnosed and treated, and has claimed that if the symptoms were felt by males, far more effort and research would have been done by that moment. In the end the committee kept PMDD in the appendix.[27]

The decision has been criticized as being driven by Lilly's financial interests, and possibly by financial interests of members of the committee who had received funding from Lilly.[27] Paula Caplan, a psychologist who had served on the committee for the DSM-IV, noted at the time of the DSM-IV-TR decision that there was evidence that calcium supplements could treat PMDD but the committee gave it no attention. She had also claimed that the diagnostic category is harmful to women with PMDD, leading them to believe they are mentally ill, and potentially leading others to mistrust them in situations as important as job promotions or child custody cases.[27] She has called PMDD a fake disorder.[57] Nada Stotland has expressed concern that women with PMDD may actually have a more serious condition like major depressive disorder or may be facing difficult circumstances—such domestic abuse—and therefore may have their true issues remain undiagnosed and mismanaged if their gynecologist diagnoses them with PMDD and gives them drugs to treat it.[27]

The validity of PMDD was once more heavily debated when it came time to create the DSM-5 in 2008.[58][59] In the end it was moved out of the appendix and into the main text as a formal category. A review in the Journal of Clinical Psychiatry published in 2014 examined the arguments against inclusion, which it summarized as: (1) the PMDD label will harm women economically, politically, legally, and domestically; (2) there is no equivalent hormone-based medical label for males; (3) the research on PMDD is faulty; (4) PMDD is a culture-bound condition; (5) PMDD is due to situational, rather than biological, factors; and (6) PMDD was fabricated by pharmaceutical companies for financial gain.[60] Each argument was addressed and researchers found: (1) No evidence of harm; (2) no equivalent hormone-driven disorder has been discovered in men despite research seeking it; (3) the research base has matured and many more reputable studies have been performed; (4) several cases of PMDD have been reported or identified; (5) a small minority of women do have the condition; and (6) while there has been financial conflict of interest, it has not made the available research unusable.[2][60] It concluded that women have historically been under-treated and told that they were making their symptoms up, and that the formal diagnostic criteria would spur more funding, research, diagnosis and treatment for women with PMDD.[60]

References modifier

  1. ↑ a b c d e f g h i j k l m n et o (en) Diagnostic and Statistical Manual of Mental Disorders (5th Edition), American Psychiatric Association, , p. 625.4 Code: 625.4 (N94.3)
  2. ↑ a b c d e f g h et i (en) Kimberly Ann Yonkers, Shaughn O'Brien et Elias Eriksson, « Premenstrual syndrome », The Lancet, vol. 371, no 9619,‎ , p. 1200–1210 (PMID 18395582, PMCID 3118460, DOI 10.1016/S0140-6736(08)60527-9)
  3. ↑ a b c d e f g h i j k et l (en) AJ Rapkin et EI Lewis, « Treatment of premenstrual dysphoric disorder », Women's Health, vol. 9, no 6,‎ , p. 537–56 (PMID 24161307, DOI 10.2217/whe.13.62)
  4. ↑ a b c d e f g h i j k l m n o p et q (en) Robert Reid et Claudio Soares, « Premenstrual Dysphoric Disorder: Contemporary Diagnosis and Management », Journal of Obstetrics and Gynaecology Canada, vol. 40, no 2,‎ , p. 215–223 (PMID 29132964, DOI 10.1016/j.jogc.2017.05.018)
  5. ↑ (en) Corey E. Pilver, Daniel J. Libby et Rani A. Hoff, « Premenstrual Dysphoric Disorder as a correlate of suicidal ideation, plans, and attempts among a nationally representative sample », Social Psychiatry and Psychiatric Epidemiology, vol. 48, no 3,‎ , p. 437–446 (ISSN 0933-7954, PMID 22752111, PMCID 3774023, DOI 10.1007/s00127-012-0548-z)
  6. ↑ a et b Teri Pearlstein, « Treatment of Premenstrual Dysphoric Disorder: Therapeutic Challenges », Expert Review of Clinical Pharmacology, vol. 9, no 4,‎ , p. 493–96 (PMID 26766596, DOI 10.1586/17512433.2016.1142371)
  7. ↑ a b c et d John Studd et Rossella E Nappi, « Reproductive depression », Gynecological Endocrinology, vol. 28, no s1,‎ , p. 42–45 (PMID 22394303, DOI 10.3109/09513590.2012.651932)
  8. ↑ M Steiner, M Macdougall et E Brown, « The premenstrual symptoms screening tool (PSST) for clinicians », Archives of Women's Mental Health, vol. 6, no 3,‎ , p. 203–209 (PMID 12920618, DOI 10.1007/s00737-003-0018-4)
  9. ↑ a b c d e f g et h M Steiner, T Pearlstein, LS Cohen, J Endicott, SG Kornstein, C Roberts, DL Roberts et K Yonkers, « Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs », Journal of Women's Health, vol. 15, no 1,‎ , p. 57–69 (PMID 16417420, DOI 10.1089/jwh.2006.15.57) Erreur de référence : Balise <ref> incorrecte : le nom « :53 » est défini plusieurs fois avec des contenus différents.
  10. ↑ WS Biggs et RH Demuth, « Premenstrual syndrome and premenstrual dysphoric disorder », American Family Physician, vol. 84, no 8,‎ , p. 918–24 (PMID 22010771)
  11. ↑ a b et c Hantsoo Liisa, « What is PMDD? », sur IAPMD, (consulté le ) Erreur de référence : Balise <ref> incorrecte : le nom « :222 » est défini plusieurs fois avec des contenus différents.
  12. ↑ WS Biggs et RH Demuth, « Premenstrual syndrome and premenstrual dysphoric disorder », American Family Physician, vol. 84, no 8,‎ , p. 918–24 (PMID 22010771)
  13. ↑ a et b « Premenstrual dysphoric disorder and psychiatric co-morbidity », Archives of Women's Mental Health, vol. 7, no 1,‎ , p. 37–47 (PMID 14963731, DOI 10.1007/s00737-003-0027-3)
  14. ↑ SL Douma, C Husband, ME O'Donnell, BN Barwin et AK Woodend, « Estrogen-related mood disorders: reproductive life cycle factors », Advances in Nursing Science, vol. 28, no 4,‎ , p. 364–75 (PMID 16292022, DOI 10.1097/00012272-200510000-00008)
  15. ↑ SL Douma, C Husband, ME O'Donnell, BN Barwin et AK Woodend, « Estrogen-related mood disorders: reproductive life cycle factors », Advances in Nursing Science, vol. 28, no 4,‎ , p. 364–75 (PMID 16292022, DOI 10.1097/00012272-200510000-00008)
  16. ↑ a et b DR Rubinow et PJ Schmidt, « Gonadal steroid regulation of mood: the lessons of premenstrual syndrome », Frontiers in Neuroendocrinology, vol. 27, no 2,‎ , p. 210–216 (PMID 16650465, DOI 10.1016/j.yfrne.2006.02.003)
  17. ↑ a et b TV Nguyen, JM Reuter, NW Gaikwad, DM Rotroff, HR Kucera, A Motsinger-Reif, CP Schmidt, LK Nieman et DR Rubinow, « The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback », Translational Psychiatry, vol. 7, no 8,‎ , e1193 (PMID 28786978, PMCID 5611719, DOI 10.1038/tp.2017.146)
  18. ↑ a b c et d « Premenstrual Dysphoric Disorder: Epidemiology and Treatment », Current Psychiatry Reports, vol. 17, no 11,‎ , p. 87 (PMID 26377947, PMCID 4890701, DOI 10.1007/s11920-015-0628-3)
  19. ↑ Kenneth S Kendler, Laura M Karkowski, Linda A Corey et Michael C Neale, « Longitudinal Population-Based Twin Study of Retrospectively Reported Premenstrual Symptoms and Lifetime Major Depression », The American Journal of Psychiatry, vol. 155, no 9,‎ , p. 1234–1240 (PMID 9734548, DOI 10.1176/ajp.155.9.1234, lire en ligne)
  20. ↑ John T Condon, « The Premenstrual Syndrome: A Twin Study », The British Journal of Psychiatry, Cambridge University Press, vol. 162, no 4,‎ , p. 481–486 (PMID 8481739, DOI 10.1192/bjp.162.4.481)
  21. ↑ Carol A Wilson, Charles W Turner et William R Keye, « Firstborn adolescent daughters and mothers with and without premenstrual syndrome: a comparison », Journal of Adolescent Health, vol. 12, no 2,‎ , p. 130–137 (PMID 2015237, DOI 10.1016/0197-0070(91)90455-U)
  22. ↑ a et b B Namavar Jahromi, S Pakmehr et H Hagh-Shenas, « Work stress, premenstrual syndrome and dysphoric disorder: are there any associations? », Iranian Red Crescent Medical Journal, vol. 13, no 3,‎ , p. 199–202 (PMID 22737463, PMCID 3371938)
  23. ↑ a et b AL Gollenberg, ML Hediger, SL Mumford, BW Whitcomb, KM Hovey, J Wactawski-Wende et EF Schisterman, « Perceived stress and severity of perimenstrual symptoms: the BioCycle Study », Journal of Women's Health, vol. 19, no 5,‎ , p. 959–67 (PMID 20384452, PMCID 2875955, DOI 10.1089/jwh.2009.1717)
  24. ↑ a et b N Dubey, JF Hoffman, K Schuebel, Q Yuan, PE Martinez, LK Nieman, DR Rubinow, PJ Schmidt et D Goldman, « The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder », Molecular Psychiatry, vol. 22, no 8,‎ , p. 1172–1184 (PMID 28044059, PMCID 5495630, DOI 10.1038/mp.2016.229)
  25. ↑ a b c d et e C Neill Epperson, Meir Steiner, S Ann Hartlage, Elias Eriksson, Peter J Schmidt, Ian Jones et Kimberly A Yonkers, « Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5 », The American Journal of Psychiatry, vol. 169, no 5,‎ , p. 465–475 (PMID 22764360, PMCID 3462360, DOI 10.1176/appi.ajp.2012.11081302)
  26. ↑ a b et c « When should surgical treatment be considered for premenstrual dysphoric disorder? », Menopause International, vol. 18, no 2,‎ , p. 77–81 (PMID 22611227, DOI 10.1258/mi.2012.012009)
  27. ↑ a b c d e f g h i et j AL Kepple, EE Lee, N Haq, DR Rubinow et PJ Schmidt, « History of postpartum depression in a clinic-based sample of women with premenstrual dysphoric disorder », Journal of Clinical Psychiatry, vol. 77, no 4,‎ , p. 415–420 (PMID 27035701, PMCID 6328311, DOI 10.4088/JCP.15m09779)
  28. ↑ a b et c Tory A Eisenlohr-Moul, Susan S Girdler, Katja M Schmalenberger, Danyelle N Dawson, Pallavi Surana, Jacqueline L Johnson et David R Rubinow, « Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS) », The American Journal of Psychiatry, vol. 174, no 1,‎ , p. 51–59 (PMID 27523500, PMCID 5205545, DOI 10.1176/appi.ajp.2016.15121510)
  29. ↑ a et b J Endicott, J Nee et W Harrison, « Daily Record of Severity of Problems (DRSP): reliability and validity », Archives of Women's Mental Health, vol. 9, no 1,‎ , p. 41–49 (PMID 16172836, DOI 10.1007/s00737-005-0103-y)
  30. ↑ (en) Christine Ro, « The overlooked condition that can trigger extreme behaviour », sur www.bbc.com (consulté le )
  31. ↑ RL Spitzer et JC Wakefield, « DSM-IV diagnostic criterion for clinical significance: does it help solve the false positives problem? », The American Journal of Psychiatry, vol. 156, no 12,‎ , p. 1856–64 (PMID 10588397, DOI 10.1176/ajp.156.12.1856, lire en ligne)
  32. ↑ Sébastien Grenier, Michel Préville, Richard Boyer, Kieron O'Connor, Sarah-Gabrielle Béland, Olivier Potvin, Carol Hudon et Joëlle Brassard, « The Impact of DSM-IV Symptom and Clinical Significance Criteria on the Prevalence Estimates of Subthreshold and Threshold Anxiety in the Older Adult Population », The American Journal of Geriatric Psychiatry, vol. 19, no 4,‎ , p. 316–326 (PMID 21427640, PMCID 3682986, DOI 10.1097/JGP.0b013e3181ff416c)
  33. ↑ a et b « Premenstrual Syndrome, Management (Green-top Guideline No. 48) », sur Royal College of Obstetricians and Gynaecologists,
  34. ↑ ICD-11: GA34.41 Premenstrual dysphoric disorder
  35. ↑ (en) Nancy Worcester et Marianne N Whatley, Women's Health: Readings on Social, Economic, and Political Issues, Sage Publications, , 613 p.
  36. ↑ « ICD-11 - Mortality and Morbidity Statistics », sur icd.who.int (consulté le )
  37. ↑ a et b PM O'Brien, T Bäckström, C Brown, L Dennerstein, J Endicott, CN Epperson, E Eriksson, E Freeman et U Halbreich, « Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus », Archives of Women's Mental Health, vol. 14, no 1,‎ , p. 13–21 (PMID 21225438, PMCID 4134928, DOI 10.1007/s00737-010-0201-3)
  38. ↑ R Moynihan, « Controversial disease dropped from Prozac product information », BMJ, vol. 328, no 7436,‎ , p. 365 (PMID 14962861, PMCID 341379, DOI 10.1136/bmj.328.7436.365)
  39. ↑ « Sertraline (Zoloft), fluoxetine (Lovan, Prozac) for premenstrual dysphoric disorder (PMDD) », sur National Prescribing Service Limited
  40. ↑ « PMDD/PMS », sur MGH Center for Women's Mental Health,
  41. ↑ (en) Amma A Agyemang, Encyclopedia of Clinical Neuropsychology, Switzerland, Springer, Cham, (ISBN 978-3-319-57111-9, DOI 10.1007/978-3-319-57111-9)
  42. ↑ E Eriksson, J Endicott, B Andersch, J Angst, K Demyttenaere, F Facchinetti, M Lancznik, S Montgomery et G Muscettola, « New perspectives on the treatment of premenstrual syndrome and premenstrual dysphoric disorder », Archives of Women's Mental Health, vol. 4, no 4,‎ , p. 111–119 (DOI 10.1007/s007370200009)
  43. ↑ a b et c (en) Susan Ward, Maternal-Child Nursing Care, Philadelphia, PA, USA, F.A. Davis Company, (ISBN 9780803636651)[page à préciser]
  44. ↑ a et b « The pharmacologic management of premenstrual dysphoric disorder », Expert Opinion on Pharmacotherapy, vol. 9, no 3,‎ , p. 429–45 (PMID 18220493, DOI 10.1517/14656566.9.3.429)
  45. ↑ « Fluoxetine elevates allopregnanolone in female rat brain but inhibits a steroid microsomal dehydrogenase rather than activating an aldo-keto reductase », British Journal of Pharmacology, vol. 171, no 24,‎ , p. 5870–80 (PMID 25161074, PMCID 4290723, DOI 10.1111/bph.12891)
  46. ↑ « Elevation of brain allopregnanolone rather than 5-HT release by short term, low dose fluoxetine treatment prevents the estrous cycle-linked increase in stress sensitivity in female rats », European Neuropsychopharmacology, vol. 25, no 1,‎ , p. 113–23 (PMID 25498416, DOI 10.1016/j.euroneuro.2014.11.017, lire en ligne)
  47. ↑ « Venlafaxine in the treatment of premenstrual dysphoric disorder », Obstetrics and Gynecology, vol. 98, no 5 Pt 1,‎ , p. 737–44 (PMID 11704162, DOI 10.1016/s0029-7844(01)01530-7)
  48. ↑ « Oral contraceptives containing drospirenone for premenstrual syndrome », The Cochrane Database of Systematic Reviews, vol. 2, no 2,‎ , p. CD006586 (PMID 22336820, DOI 10.1002/14651858.CD006586.pub4)
  49. ↑ « Premenstrual disorders », American Journal of Obstetrics and Gynecology, vol. 218, no 1,‎ , p. 68–74 (PMID 28571724, DOI 10.1016/j.ajog.2017.05.045)
  50. ↑ KA Yonkers et MK Simoni, « Premenstrual disorders », American Journal of Obstetrics and Gynecology, vol. 218, no 1,‎ , p. 68–74 (PMID 28571724, DOI 10.1016/j.ajog.2017.05.045)
  51. ↑ « Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome », The New England Journal of Medicine, vol. 338, no 4,‎ , p. 209–16 (PMID 9435325, DOI 10.1056/NEJM199801223380401)
  52. ↑ « Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels », The American Journal of Psychiatry, vol. 174, no 10,‎ , p. 980–989 (PMID 28427285, PMCID 5624833, DOI 10.1176/appi.ajp.2017.16101113)
  53. ↑ a b et c « Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: a meta-analysis », Journal of Clinical Psychology in Medical Settings, vol. 19, no 3,‎ , p. 308–19 (PMID 22426857, DOI 10.1007/s10880-012-9299-y)
  54. ↑ (en) Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition Revised, American Psychiatric Association, (DOI 10.1176/appi.books.9780890420188.dsm-iii-r)
  55. ↑ a et b (en) Carla Spartos, « Sarafem Nation », Village Voice,‎ (lire en ligne)
  56. ↑ (en) Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, American Psychiatric Association, (DOI 10.1176/appi.books.9780890420249.dsm-iv-tr)
  57. ↑ M Steiner, S Steinberg, D Stewart, D Carter, C Berger, R Reid, D Grover et D Streiner, « Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group », New England Journal of Medicine, vol. 332, no 23,‎ , p. 1529–34 (PMID 7739706, DOI 10.1056/NEJM199506083322301)
  58. ↑ Paula J Caplan, « The Debate About PMDD and Sarafem », Women & Therapy, vol. 27, nos 3–4,‎ , p. 55–67 (DOI 10.1300/J015v27n03_05)
  59. ↑ (en) Ingfei Chen, « A Clash of Science and Politics Over PMS », The New York Times,‎ (lire en ligne)
  60. ↑ a b et c S. Ann Hartlage, Cynthia A Breaux et Kimberly A Yonkers, « Addressing Concerns About the Inclusion of Premenstrual Dysphoric Disorder in DSM-5 », The Journal of Clinical Psychiatry, vol. 75, no 1,‎ , p. 70–76 (PMID 24345853, DOI 10.4088/JCP.13cs08368)

External links modifier

Modèle:Medical resources

Modèle:Menstrual cycle


Ce document provient de « https://fr.wikipedia.org/w/index.php?title=Utilisateur:Lyokoï/Brouillon&oldid=170613533 ».